Claims for Patent: 11,026,944

Summary for Patent: 11,026,944

Title:	Compositions and methods for treating insomnia
Abstract:	In the present invention, compound such as (1R,2S)-2-(((2,4-dimethylpyrimidin-5-yl)oxy)methyl)-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl) cyclopropanecarboxamide have been found to be potent orexin receptor antagonists, and may be useful in the treatment of sleep disorders such as insomnia, as well as for other therapeutic uses.
Inventor(s):	Margaret Moline, Gina PASTINO, Yurie AKIMOTO, Yasuhiro Zaima, Nobuya Suzuki, Nobuo Yoshida
Assignee:	Eisai R&D Management Co Ltd
Application Number:	US16/819,341
Patent Claims:	1. A dosage form comprising a therapeutically effective amount of compound A, wherein said therapeutically effective amount is a single daily dose ranging from about 2.5 mg to about 10 mg, wherein said dosage form provides a dissolution rate of 85% or more in a dissolution medium (0.1 mol/L hydrochloric acid containing 0.5% polysorbate 80, 900 mL, 37±0.5° C.) within 30 minutes from the onset of a dissolution study using Apparatus 2 (Paddle Apparatus, paddle speed; 75 rpm) according to the procedure for immediate-release dosage form in 6.10 Dissolution test of JP16 or <711>Dissolution of USP37, wherein said compound A is (1R,2S)-2-(((2,4-dimethylpyrimidin-5-yl)oxy)methyl)-2-(3-fluorophenyl)-N-(5-fluoropyridine-2-yl)cyclopropanecarboxamide represented by the following formula: 2. The dosage form of claim 1, wherein said dosage form provides a dissolution rate of 85% or more in a dissolution medium (0.1 mol/L hydrochloric acid, 900 mL, 37±0.5° C.) within 15 minutes from the onset of a dissolution study using Apparatus 2 (Paddle Apparatus, paddle speed; 50 rpm) according to the procedure for immediate-release dosage form in 6.10 Dissolution test of JP16 or <711>Dissolution of USP37. 3. The dosage form of claim 1, wherein said dosage form comprises lactose as a pharmaceutically acceptable excipient. 4. The dosage form of claim 1, wherein said dosage form comprises low-substituted hydroxypropyl cellulose as a pharmaceutically acceptable excipient. 5. The dosage form of claim 1, wherein said dosage form comprises lactose and low-substituted hydroxypropyl cellulose as pharmaceutically acceptable excipients.